Described herein are dosing regimens and kits comprising (3R, 4R, 5S)-5-(difluoromethyl)piperidine-3.4-diol for the treatment and/or prevention of lysosomal storage disorders such as Gaucher disease. Also described are dosing regimens and kits comprising (3R, 4R, 5S)-5-(difluoromethyl)piperidine-3.4-diol for the treatment and/or prevention of degenerative disorders of the central nervous system, such as the synucleinopathies Parkinson's disease or Lewy Body Dementia.
REGIMENS FOR TREATING AND PREVENTING LYSOSOMAL DISORDERS AND DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM